Boris Pasche

This study identifies key oncogenic pathways and targetable genes in MEN1-wild-type low-grade pancreatic NETs that drive metastasis, offering a therapeutic strategy based on pathway intensity rather than mutation count.

This study shows that combining PCNA inhibitor AOH1996 with KRAS inhibitors enhances antitumor activity in pancreatic cancer models.

This paper shows that combining Eltanexor and MRTX1133 improves efficacy in KRASG12D mutant PDAC by overcoming resistance and reducing tumor growth.

This study identifies RCC1 as a novel therapeutic target in PDAC, showing its role in tumor progression and drug resistance through the c-Myc-RCC1-Ran axis.

This study analyzes SMARCA4 mutations in KRAS-mutant lung adenocarcinoma across multiple cohorts, finding adverse clinical outcomes associated with SMARCA4 mutations in both non-immunotherapy and immunotherapy-treated patients.